4,4-Disubstituted piperidines, and methods of use thereof

Details 4,4-Disubstituted piperidines, and methods of use thereof 4,4-Disubstituted piperidines, and methods of use thereof

2007-05-15

2007-05-15

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S207000

Reexamination Certificate

active

10722114

ABSTRACT:
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

REFERENCES:
patent: 2538107 (1951-01-01), Kwartler et al.
patent: 2966491 (1960-12-01), Pfister et al.
patent: 3108111 (1963-10-01), Stern et al.
patent: 4485109 (1984-11-01), Ciganek
patent: 5118693 (1992-06-01), Toth et al.
patent: 5807865 (1998-09-01), Harrison et al.
patent: 5968955 (1999-10-01), Mantegani et al.
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6159990 (2000-12-01), Lagu et al.
patent: 6211198 (2001-04-01), Gluchowski et al.
patent: 0 337 167 (1989-01-01), None
patent: 0 412 822 (1994-04-01), None
patent: 1.477.152 (1967-03-01), None
patent: WO 9106297 (1991-05-01), None
patent: WO 94/10165 (1994-05-01), None
patent: WO 95/19344 (1995-07-01), None
patent: WO 97/32852 (1997-09-01), None
patent: WO 9857972 (1998-12-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/58501 (1999-11-01), None
Caplus English Abstract DN 91:168231, Rehse et al 1979 , vol. 312, Issue 8 pp. 670681.
Joseph DeGraw et al , Histamine Releasers 1967, vol. 10 pp. 174-177.
Caplus English Abstract , DN 106:18327 ,1986, vol. 319(6) pp. 505-515.
Caplus English Abstract JP 59106460 Jun. 1984 Fujisawa Pharmaceutical.
Caplus English Abstract 94:57952 , Yamato Masatoshi et al , 1981, vol. 24 (2) pp. 194-198.
Caplus , English Abstract 54:7351 , GB 815926 , US 2966491 , Merck and Co. Jul. 1959.
Caplus English Abstract DN 54:39146 , GB 817357, Jul. 1959 , Merck and Co.
Brine et al.; “Synthesis of 4,4- Disubstituted Piperidine Analogs of (±)-cis-N-[I-(2-Hydroxy-2-phenylethyl)-3- Methyl-4-piperidyl]-N-phenyipropanamide”, Journal of Heterocyclic Chemistry, 31(2):513-520, (Mar.-Apr. 1994).
Colapret et al.; “Synthesis and Pharmacological Evaluation of 4,4-Disubstituted Piperidines”, J. Med. Chem. 32: 968-974, (1989).
Huegi et al.; “Synthesis and Pharmacological Studies of 4,4-Disubstituted Peperidines: A New Class of Compound with Potent Analgesic Properties”, J. Med. Chem. 26: 42-50, (1983).
Lewis et al.; “An Efficient Protocol for the Preparation of Primary Alcohols Bearing a β-Chiral Center Via an Oxazolidinone Auxiliary Mediated Resolution, and Application to the Synthesis of 4,4-Disubstituted Piperidine Substance P Antagonist”, J. Org. Chem. 65: 2615-2618, (2000).
Huybrechts and Hoornaert; “2-Bromo-N-(2-Bromoethyl)-N-Carbethoxyethanamine, A Useful Reagent in the Synthesis of 4,4 Disubstituted piperidines”, Synthetic Communication, 11 (1): 17-23, (1981).
Stevenson et al.; “4,4-Disubstituted Piperidines: A New Class of NKI Antagonist”, J. Med. Chem. 38: 1264-1266, (1995).
DeGraw et al.; “Histamine Releasers. III. Dibasic Acid Amides of 4-phenyl-4Aminomethylpiperidines”, J. Med. Chem. 10(2): 174-177, (1967).
Gervais et al.; “Cyciodeshydration D'Alcool Phenol Induite par L'H.M.P.A. Nouvelle voie D'Acces aux Dihydrobenzofurannes et Dihydrobenzopyrannes”, Tetrahedron 35: 745-752, (1979).
Rehse and Werner; “Antiaggregatorische and Anticoagulante Eigenschaften von Oligoaminen+ 1 Mitt”, Arch. Pharm. 319(6): 505-515, (1986).
Rehse et al.; “Neuropsychotrope Aktivitat Dopaminanaloger Piperidin-Und Piperazinderivatite”, Arch. Pharm. (Weinheim) 312:670-681 (1979).
Stevenson et al.; “4,4-Disubstituted Piperidine High-Affinity NK1Anntagonists: Structure-Activity Relationships and in Vivo Activity”, J. Med. Chem. 41: 4623-4635, (1998).
Yamato et al.; “Synthesis and Biological Activity of Spiro[isocoumarin-piperidines] and Related Compounds”, Chem. Pharm. Bull. 29(2): 402-405, (1981).
Annex to Form PCT/ISA/206 Showing Partial International Search Report Mailed on Jul. 7, 2002.

Affiliated with

Also associated with

Rating

4,4-Disubstituted piperidines, and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4,4-Disubstituted piperidines, and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4,4-Disubstituted piperidines, and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3770945